Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors

Purpose LY2334737 is an oral gemcitabine prodrug. This Phase I study assessed the safety and tolerability of LY2334737 in Japanese patients with solid tumors and evaluated pharmacokinetics (PK), pharmacodynamics, and antitumor activity.